Overview

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia

Status:
RECRUITING
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia in postmenopausal women with osteoporosis at high risk of fracture.
Phase:
PHASE3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Denosumab
QL1206